Abstract The mode of action of annexin A1 (ANXA1) is poorly understood. By using rapid subtraction hybridization we studied the effects of human recombinant ANXA1 and the N-terminal ANXA1 peptide on gene expression in a human larynx cell line. Three genes showed strong downregulation after treatment with ANXA1. In contrast, expression of CCR10, a seven transmembrane G-protein coupled receptor for chemokine CCL27 involved in mucosal immunity, was increased. Moreover the reduction in CCR10 expression induced by ANXA1 gene deletion was rescued by intravenous treatment with low doses of ANXA1. These findings provide new evidence that ANXA1 modulates gene expression.
Introduction
Annexin A1 (ANXA1) is a 37 kDa member of a family of Ca 2+ -regulated lipid-binding proteins [1] . Functional studies have identified roles for ANXA1 and its N-terminal domain [2, 3] in the regulation of inflammation [4] , the cell cycle [5] and as a mediator of glucocorticoid action on the release of corticotrophin (ACTH) from the anterior pituitary gland [6, 7] . Many of the regulatory actions of ANXA1 in these systems have been shown to emerge promptly, i.e., within minutes to hours of contact with the protein [6] . Whilst some have been ascribed to the ability of ANXA1 to act intracellularly to disrupt signalling cascades [8] , others appear to reflect interactions with cell surface receptors [9] [10] [11] . Recent studies suggest that members of the formyl peptide receptor (FPR) family of G-protein coupled receptors are particularly important in this regard [12, 13] . Three members of this receptor family have been identified in human, termed FPR, FPRL1 and FPRL2. Receptor-specific ligands are not yet available, but FPR is highly sensitive to the bacterial peptide formyl-Met-Leu-Phe (fMLP), while FPRL1 shows some selectivity for lipoxin A4, a lipid metabolite, in addition to responding to high concentrations of fMLP [14] .
Despite the evidence that ANXA1 might influence cellular responsiveness, the possibility that ANXA1 regulates gene expression has received scant attention. Interestingly however, the recently generated ANXA1 knockout mouse shows significant alterations in the expression of a number of gene products associated with inflammation [15, 16] , a finding that concurs with earlier reports that ANXA1 reduces the expression of inducible nitric oxide synthase [17] .
We have used rapid subtraction hybridisation (RaSH) [18] to investigate the effects of ANXA1 Ac2-26 on gene expression in a human cell line of epithelial origin. In addition, we have compared the effects of hrANXA1 and ANXA1 Ac2-26 with those of fMLP (a bacterial peptide) and the stable analogue of lipoxin A4 [15-epi-16-(para-fluoro)-phenoxy-LXA4-methyl ester, ATLa-ME], an arachidonic acid metabolite, in order to explore the role of the FPR family in effecting the response to ANXA1. The data obtained from the cell line in vitro have been evaluated in vivo by studies on Anxa1 null mice. Our findings strongly support a role for ANXA1 in the regulation of gene expression, particularly those genes concerned with the inflammatory response.
Materials and methods

Drugs
Human recombinant annexin A1, [19] was produced, purified and tested by SDS-PAGE for the presence of cleaved forms which were not detected, by Scientific Proteins, Witterswil, Switzerland. Furthermore, the recombinant protein did not show any phosphorylation at the N-terminal as reported previously [19] . Human ANXA1 Ac2-26 (acetylated peptide at the N-terminal) was synthesized in the Advanced Biotechnology Centre, Imperial College London, UK. The peptide fMLP was purchased from Sigma (Sigma-Aldrich Corp., Poole, Dorset, UK) and 15-epi-16-(para-fluoro)-phenoxy-ATLA-methyl ester (ATLa, the methyl ester of lipoxin A4) was a generous gift from Professor C. Serhan (Harvard Medical School, Boston, USA). The doses of acetylated peptide (ANXA1 Ac2-26 ; 2 lM) were chosen on the basis of previous studies, performed both in vitro and in vivo, in which we showed that comparable biological activity were obtained when the ratio between fMLP or ATLa and ANXA1 Ac2-26 was 1:20 [13, 20] furthermore such molar ratio was of 1:15 between the entire recombinant ANXA1 and the peptide Ac2-26 as described previously [21] .
Cell culture
The Hep-2 cell lines were derived from a human larynx epidermoid carcinoma cells (ATCC Rockville, MD, USA) and used for RaSH analysis. The PDFS cell line derived from a clinically non-functioning pituitary macroadenoma was used to confirm and compare the analysis performed on Hep-2 cells (see supplement Table 2 ) [22] .
Animals
Male Anxa1-null mice aged approximately 4 months old [15] and weighing 30 ± 4 g were used together with age-and sex-matched wild type controls. All animals were fed on a standard chow pellet diet. All procedures were carried out under licence in accordance with the UK Animals (Scientific Procedures) Act, 1986. For tissue collection the animals were killed by cervical dislocation and their lower back region was shaved. Longitudinal fragments of the dorsal skin (after shaving), trachea and ileum were obtained from each mouse (6 animals per tissue) and frozen immediately in liquid nitrogen for subsequent extraction of RNA and protein.
Anxa1 null mice were injected intravenously via the lateral tail vein with hrANXA1 (10 ng/mouse), ANXA1 Ac2-26 (14 ng/mouse) or a corresponding volume of the saline vehicle (100 ll). Mice (three animals per treatment) were killed with CO 2 , 24 h after drug administration, and tissues collected exactly as described above.
Rapid subtraction hybridization (RaSH) and RT-PCR analysis
Hep-2 cells were plated at a concentration of 10 6 cells/in six well plates (Corning Incorporated, NY, USA) and 24 h later in culture, stimulated with ANXA1 Ac2-26 (2 lM; 72 h). Total RNA isolated by RNeasy (Qiagen, West Sussex, England) from control and treated cells were used for double-stranded cDNA synthesis using a standard protocol [23] . The DNA was then digested and mixed with the adaptors XPDN-14/XPDN-12 (Sigma Genosys; final concentration 20 lM) as described by Jiang et al. [18] . 100 ng tester cDNA (e.g., untreated cells) was mixed with 5 lg driver cDNA (e.g., ANXA1 Ac2-26 treated cells, see also Table 1 ) in hybridization solution [18, 24] . After extraction and precipitation the hybridization mixtures (1 lg) were ligated to an XhoI digested pCDNA3 plasmid and transformed in competent bacteria. Bacterial colonies were selected randomly and amplified by PCR. The sequences of these clones were determined using the automated cycle sequencer in the Advanced Biotechnology Centre, Imperial College London. Sequences were compared with the NCBI nucleotide bank (GenBank) allowing identification of any genes up or down regulated. Experiments were then set up (n = 3) in the same conditions described above and RT-PCR with specific oligonucleotides (supplementary data Table 1 ) for the genes identified by RaSH was performed.
Semi quantitative RNA analysis
We first determined the linear range of amplification (25, 20, 35 , 40 cycles) of cDNA using each of the primer sets. Amplification was within the linear range for all genes studies when 35 PCR cycles were used and this level of amplification was therefore used in all further studies. For each sample 5 ll of the PCR amplification products was analysed on 2% agarose gels and stained with ethidium bromide. The intensities of the bands were compared to GAPDH in each sample and evaluated using the Image Master Software (SYDR-1990, SYNGENE, USA).
Western blot analysis
Expression of CCR10 (GPR2) protein (15 lg) was examined in the cell lines and murine tissue extracts by SDS-PAGE, then transferred electrophoretically to nitrocellulose paper [25] . The blots were incubated overnight at 4°C in incubation buffer in presence of an anti-CCR10 antiserum (diluted 1:1000, goat anti-mouse polyclonal, Abcam; or anti human CCR10 diluted 1:1000, Imgenex San Diego, CA, USA). Immunoreactive protein bands were detected by chemiluminescence (GE Healthcare, UK) after incubation with secondary antibody (rabbit anti-goat peroxidase; 1: 100 000, Biomeda; or goat anti-rabbit peroxidase conjugated antiserum, 1:25 000, Sigma-Aldrich Corp.). The blots were then scanned and analyzed (HP Scanjet 5200 with Adobe Photodeluxe Business Edition, version 1.1; Cupertino, CA). The intensities of the bands were compared to b-actin (mouse monoclonal 1:5000, Abcam).
FACS analysis
For detection of FPR and FPRL1 on the cell surface of Hep-2 and PDFS cells, aliquots of suspensions of the cells (10 5 cells in 100 ll) were added to a 96-flat well plate in triplicate and incubated at 4°C for 1 h in the presence or absence (controls) of either: (a) a monoclonal antihuman FPR antibody (1:100, BD Pharmingen) or mouse IgG1 clone NOPC-21 (isotype-matched control antibody 1:100, BD Pharmingen, UK) or (b) a rabbit anti-human FPRL1 polyclonal antiserum raised against the peptide TVWLKEMLFYGKYKIIDILVNP from the 3rd extracellular domain of the receptor (1:100, Neosystem Strasburg, France). Non-specific binding was minimized by the addition of human IgG (1.6 mg/ml, Roche Diagnostics, Lewes, UK). After incubation with the primary antiserum, the cells were incubated on ice for 30 min with FITC-conjugated rabbit anti-mouse or sheep anti-rabbit IgG (1:300, Serotec, Kidlington, Oxford, UK). The cell surface fluorescence was analyzed immediately by flow cytometry using a Becton Dickinson FACScan II analyzer. At least 10 000 cells per sample were counted. The data were analyzed as units of fluorescence measured in the FL1 channel (mean fluorescence intensity). A similar method was used to detect and quantify expression of the cell surface receptor CCR10 (GPR2) using a goat anti-rabbit polyclonal antibody to CCR10 (GPR2, 1:100, Imgenex San Diego, CA, USA) as a probe and FITC-conjugated sheep anti-rabbit IgG (1:300, Serotec) for detection.
Statistical analysis
Statistical significance was assessed by ANOVA followed by Bonferroni's t test, and P < 0.05 was taken as statistically significant.
Results and discussion
Annexin A1 modulates gene expression in cell line
Subtractive hybridisation performed on the human cell line Hep-2, identified three genes, which were downregulated by hrANXA1 (100 nM) and ANXA1 Ac2-26 (2 lM) treatment. The first was ITGB1BP1 (previously named ICAP-1A, Table  1 and Fig. 1 ) a protein specifically associated with the b1 cytoplasmic domain of integrins [26] containing putative phosphorylation sites. The phosphorylated form probably impairs cell adhesion and spreading [27] , but over-expression of ITGB1BP1 stimulates cell migration [28] . Thus, the ability of ANXA1 to impair monocytes on the endothelium in vitro [21] may be mediated, at least in part, through ITGB1BP1 downregulation.
Since ANXA1 and ANXA1-derived peptides are potential ligands for members of the formyl peptide receptor (FPR) family, we explored the potential role of these receptors in Fig. 2A and B) . Subsequently, we used ligands of FPR and FPRL1, fMLP and the lipoxin A4 analogue (ATLa), to explore whether activation of these receptors modulated the expression of ITGB1BP1 (Fig. 1B and Table 3B supplement data). Neither fLMP nor ATLa, ligands for FPR and FPRL1, modified the expression of ITGB1BP1 (Fig. 1B) . Although we cannot exclude the possibility that higher concentrations of these compounds may have been effective they would be expected to act at the concentrations tested [13] and indeed have been shown to modify the expression of other genes in this study. We therefore suggest that the regulatory actions of ANXA1 and ANXA1 Ac2-26 on the expression of ITGB1BP1 were mediated via a mechanism independent of FPR or FPRL1. A second gene downregulated by both hrANXA1 and AN-XA1 Ac2-26 was a phenylalanine-tRNA synthetase (FARSLA). Unlike ITGB1BP1 this gene was also downregulated by fMLP and ATLa, suggesting a role for the FPR family in mediating the response (Fig. 1A and B) . In vivo FARSLA is expressed in a tumour-selective, cell cycle stage and differentiation-dependent manner and its expression is augmented in tumourigenic versus non-tumourigenic variant of the same cell line [29] . Interactions between ANXA1 and aminoacyl-tRNa synthase have been reported in patients with dermatomyositis [30] and between ANXA1 and tryptophanyl-tRNA synthetase [31] . Together, these results raise the possibility that ANXA1 plays a role in cell transformation as well as in protein translation and may explain why it is highly expressed in some cancers and not in others [32] . Interestingly, it has been proposed that ANXA1 and tRNA synthase share some physiological role in process related to myositis and immune response [31] .
A third gene downregulated by ANXA Ac2-26 and fMLP, but not by ANXA1 or ATLa (Fig. 1A and B) was a TRAF-interacting protein with a forkhead-associated domain termed TIFA or T2BP. Although merely speculative, as we do not know how the acetylation may affect the structure and function of the peptide, the downregulation of TIFA suggests that ANXA1 may modulate inflammatory processes via TNFa and TIFA, supporting our previous findings on the role of ANXA1 in systemic endotoxemia [33] . The data on the full protein (hrANXA1) or ATLa (ligand of FPRL1 receptor), which did not affect the expression of this gene, suggest that the fulllength protein (hrANXA1) and the N-terminal peptide (AN-XA1 Ac2-26 ) act via different mechanisms and thus support a preferential binding of ANXA1 to FPRL1 receptor [13] . We have recently published data on the differential effects of the full-length protein and its peptide in the firm adhesion of human PMNs on the endothelium under flow [20] and the results demonstrated here reinforce the dichotomy in the biological activity of the acetylated peptide versus the entire molecule. In contrast to it effects on ITGB1BP1, FARSLA and TIFA, ANXA1 (which is strongly expressed in epithelial cells and skin [34] ), had a positive effect on the expression of the CCR10 gene (Table 1) , a skin homing receptor for chemokine CCL27 [35] . This effect was mimicked by ANXA1 Ac2-26 , fMLP and ATLa (Fig. 3 A and B) , supporting a role for the FPR family in mediating the positive effect of ANXA1. Support for a role of ANXA1 in CCR10 gene regulation was provided by the Western blot and FACS analysis of the protein expression and membrane localisation ( Fig. 4A and B) indicating the potential for a ligand binding activity.
Analysis of CCR10 expression in vivo
Our studies on Anxa1-null mice and wild type controls reveal a marked reduction in CCR10 expression in the Anxa1-null mice versus control (Fig. 5) and show that this is reversed by treatment with hrANXA1 or ANXA1 (Fig. 6) . However Anxa1 null mice did not show any phenotype that could readily be linked to downregulation of CCR10 and further studies are necessary to explore the significance of these findings. However, our own data (John et al. manuscript in preparation) and a recent report showing the LPS susceptibility of the Anxa1 null mice [36] open new avenues on the possible significance of changes in CCR10 expression.
As ANXA1 is commonly viewed as an anti-inflammatory protein and CCL27 is pro-inflammatory, it might have been predicted that ANXA1 would downregulate CCR10 expression. However recent studies have reported that CCR10 induction on pathogen-specific IgA-secreting B cells may be an important factor for successful protection following local mucosal infection [37] .
Conclusions
Taken together, the data provide new evidence that ANXA1 modulates gene expression. The mechanisms responsible require further investigation. While our data support a role for the FPR family in mediating some of the effects, the failure of fLMP and ATLa to suppress ITGB1BP1 suggest other mechanisms are involved. Furthermore, the dissociation between the activities of hrANXA1 and ANXA1 support the premise that the actions of ANXA1, but not ANXA1 , are akin to those of the FPRL1 ligand LXA4.
